Sage Journals: Discover world-class research

Abstract

Keywords

natriuretic peptides cardiovascular disease vasopeptidase inhibitors

Get full access to this article

View all access options for this article.

References

Klahr S. , Slatopolsky E. Renal regulation of sodium excretion. Arch Intern Med 1973; 131: 780-91.

de Wardener, HE Clarckson EM Concept of natriuretic hormone . Physiol Rev 1985: 30: 659-745.

Henry JP , Gauer OH , Reeves JL Evidence of the atrial location of receptors influencing urine flow . Circ Res 1956; 4: 85-90.

Jamieson JD , Palade GE Specific granules in atrial muscle cells. J Cell Biol 1964; 23: 151-72.

de Bold AJ Atrial natriuretic factor: a hormone produced by the heart. Science 1985; 30: 767-70.

Sagnella GA , Macgregor GA Atrial natriuretic peptides. Quart J Med 1990 ; 77: 1001-7.

Blaine EH Atrial natriuretic factor plays a significant role in body fluid homeostasis . Hypertension 1990; 15: 2-8.

John SWM , Krege JH , Oliver PM et al. Genetic decrease in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995; 267: 679-81.

Lopez MJ , Wong SK , Kishimoto I. et al. Salt resistant hypertension in mice lacking the guanylate cyclase-A receptor for atrial natriuretic peptide. Nature 1995; 378: 65-8.

10.

Gunning M. , Brenner BM Urodilatin: a potent natriuretic peptide of renal origin. Curr Opin Nephrol Hypertens 1993; 2: 857-62.

11.

Lang CC , Choy AJ , Struthers AD Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin Sci 1992; 83: 519-27.

12.

Barr CS , Rhodes P. , Struthers AD C-type natriuretic peptide. Peptides 1996; 17: 1243-51.

13.

Lisy O. , Jougasaki M. , Heublein DM et al. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney International. 1999; 56:502-8.

14.

Holmes SJ , Espiner EA , Richards AM , Yandle TG , Frampton C. Renal, endocrine, and haemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993 ; 76: 91-6.

15.

Barnett DB Heart failure. Diagnosis of symptomless left ventricular dysfunction . Lancet 1993; i: 1124-5.

16.

McDonagh TA , Morrison CE , Lawrence A. et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population . Lancet 1997; 350:829-833.

17.

De Marco T. , Goldman L. Predicting outcomes in severe heart failure . Circulation 1997; 95: 2597-9.

18.

Berlowitz DR , Ash AS , Hickey EC et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339:1957-63.

19.

Hobbs FDR . The scale of heart failure: diagnosis and management of issues for primary care. Heart 1999; 82(Suppl iv): iv8-iv10.

20.

Nakao K. , OgawaY., Suga S. , Imura H. Molecular biology and biochemistry of the natriuretic peptide system I: natriuretic peptides. J Hypertens 1992; 10: 907-12.

21.

Itoh H. , Nakao K. , SugawaraA. et al. Gamma-atrial natriuretic polypeptide (gamma ANP)-derived peptides in human plasma: cosecretion of N-terminal gamma ANP fragment and alpha ANP . J Clin Endocrinol Metab 1988;67: 429-37.

22.

Kambayashi Y. , Nakao K. , Mukoyama M. et al. Isolation and sequence determination of human brain natriuretic peptide in human atrium . FEBS Lett 1990; 259: 341-45.

23.

Richards AM Human plasma atrial natriuretic peptide concentrations in health and disease. Curr Opin Cardiol 1987 ; 2: 660-70.

24.

Sundsfjord JA , Thibault G. , Larochelle P. , Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 1988 ;66:605-10.

25.

Buckley MG , Sagnella GA , Markandu ND , Singer DRJ , MacGregor GA Concentrations of N-terminal Pro ANP in human plasma: evidence for Pro ANP (1-98) as the circulating form. Clin Chim Acta 1990; 191: 1-14.

26.

Azizi C. , Maistre G. , Kalotka H. et al. Plasma levels and molecular forms of proatrial natriuretic peptides in healthy subjects and in patients with congestive heart failure. J Endocrinol 1996;148:51-7.

27.

Mukoyama M. , Nakao K. , Hosoda K. et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest 1991 ; 87: 1402-12.

28.

Yasue H. , Yoshimura M. , Sumida H. et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.

29.

Buckley MG , Sethi D. , Markandu ND , Sagnella GA , Singer DR , MacGregor GA Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure . Clin Sci 1992;83:437-44.

30.

Kohno M. , Horio T. , Yokokawa K. et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92: 29-34.

31.

Yandle TG , Richards AM , Gilbert A. , Fisher S. , Holmes S. , Espiner EA Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure . J Clin Endocrinol Metab 1993;76:832-8.

32.

Jensen KT , Carstens J. , Ivarsen P. , Pedersen EB A new, fast and reliable radioimmunossay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab Invest 1997;57: 529-40.

33.

Buckley MG , Markandu ND , Miller MA , Sagnella GA , MacGregor GA Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. J Human Hypertens 1993;7:245-50.

34.

Hunt PJ , Yandle TG , Nicholls MG , Richards AM , Espiner EA The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995;214:1175-83.

35.

Hunt PJ , Richards AM , Nicholls MG , Yandle TG , Doughty RN , Espiner EA Immunoreactive amino-terminal pro-brain natriuretic peptide(NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997; 47: 287-96.

36.

Togashi T. , Fujita S. , Kurosawa T. , Hasegawa N. , Kikawada R. , Kawakami M. Circulating forms of B-type natriuretic peptide after acute myocardial infarction . Clin Chem 1993; 39: 550-1.

37.

Togashi K. , Kameya T. , Ando K. , Maruma F. , Kawakami M. Brain natriuretic peptides in human plasma, spinal cord and cerebrospinal fluid. Clin Chim Acta 1991; 201: 193-200.

38.

Hasegawa K. , Fujiwara H. , Doyama K. et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993;88:372-80.

39.

Morita E. , Yasue H. , Yoshimura M. et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82-91.

40.

Nishikimi T. , Yoshihara F. , Morimoto A. et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996:28: 22-30.

41.

Feldschuh J. Blood volume measurements in hypertensive disease. In: Hypertension, Pathophysiology, Diagnosis and Treatment. Laragh JH and Brenner BM (Eds). Raven Press: New York 1990: 339-47.

42.

London GM , Safar ME , Safar AL , Simon AC Blood pressure in the 'low-pressure system' and cardiac performance in essential hypertension. J Hypertens 1985 ; 3: 337-42.

43.

Haug C. , MetzeleA, Kochs M. , Hombach V. , Grunert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clinical Cardiology 1993;16:553-7.

44.

Yamamoto K. , Burnet JC Jr , Jougasaki M. et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy . Hypertension 1996; 28: 998-4

45.

Davidson NC , Naas AA , Hanson JK , Kennedy NS , Coutie WJ , Struthers AD Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction .Am J Cardiol 1996;77:828-31.

46.

Yamada Y. , Goto J. , Yokoto M. Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease. Cardiology 1997;88: 401-7.

47.

Lang CC , Prasad N. , McAlpine H. et al. Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. Am Heart J 1994; 127: 1635-6.

48.

Francis GS , Benedict C. , Johnston De et al. Comparison of neurodendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990; 82: 1724-9.

49.

Lerman A. , Gibbons R. , Rodeheffer, Bailey K , McKinley L. , Heublein D. et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341: 1105-13.

50.

Omland T. , Aakvaag A. , Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996; 76: 232-7.

51.

Muders F. , Kromer EP , Griese DP et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997; 134: 442-9.

52.

Cowie MC , Struthers AD , Wood DA et al. Value of natriuretic peptides in assesment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1347-51.

53.

McDonagh TA , Robb SD , Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351:9-13.

54.

Luchner A. , Burnett Jr, JC , Jougasaki M. et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000; 18: 1121-8.

55.

Gottlieb SS , Kukin ML , Ahern D. , Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heat failure. JAm Coll Cardiol 1989; 13: 1534-9.

56.

WallenT. , Landahal S. , HednerT. et al.Atrial natriuretic peptides predict mortality in the elderly . J Intern Med 1997; 241: 269-75.

57.

Sayama H. , Makamura Y. , Saito N. , Kinoshita M.

Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal?

Coron Artery Dis 1999 ; 10: 537-40.

58.

Horio T. , Shimada K. , Kohno M. et al. Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty. Am Heart J 1993;126:293-9.

59.

Arakawa N. , Nakamura M. , Aoki H. , Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology 1994;85:334-40.

60.

Naruse M. , Takeyama Y. , Tanabe A. et al.Atrial and brain natriuretic peptides in cardiovascular diseases . Hypertension 1994;23: 1231-4.

61.

OmlandT, Bonarjee VV , Nilsen DW et al. Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. Br Heart J 1993;70:409-14.

62.

Hall C. , Rouleau JL , Moye L. et al. N-Terminal proatrial natriuretic factor - an independent predictor of long term prognosis after myocardial infarction. Circulation 1994; 89: 1934-42.

63.

Darbar D. , Davidson NC , Gillespie N. et al. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am JCardiol 1996; 78: 284-7.

64.

Omland T. , Aakvaag A. , Bonarjee VV et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.

65.

Richards AM , Nicholls MG , Yandle TG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97: 1921-9.

66.

Tsutamoto T. , Wada A., Maedo K. et al.Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96:509-16.

67.

Yu CM , Sanderson JE Plasma brain natriuretic peptide- an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Failure 1999; 1: 59-65.

68.

Troughton RW , Frampton CM , Yandle TG , Espiner EA , Nicholls MG , Richards AM Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide(N-BNP) concentrations. Lancet 2000: 355: 1126-30.

69.

Murdoch DR , Byrne J. , Morton JJ et al. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice. Heart 1997; 78: 594-7.

70.

Clerico A. , Iervasi G. , Del Chicca MG , Emdin M. , Maffei S. , Nannipieri M. et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immuno- radiometric assays in normal subjects and in patients with different degrees of heart failure . J Endocrinol Invest 1998;21:170-9.

71.

Buckley MG , Marcus NJ , Yacoub MH , Singer DR Prolonged stability of brain natriuretic peptide: importance for non-invasive assessment of cardiac function in clinical practice. Clin Sci 1998;95:235-9.

72.

Wieczorek SJ , Bailly KR , Thomas P. et al. Clinical evaluation of the triage B-type natriuretic peptide assay for point of care testing of patients with congestive heart failure. Clin Chem 2000; 46:A77(Abstract).

73.

Chinkers M. , Garbers DL , Chang MS et al. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989;338:78-83.

74.

Nakao K. , Ogawa Y. , Suga S. -I, Imura H. Molecular biology and biochemistry of the natriuretic peptide system.II: Natriuretic peptide receptors. J Hypertens 1992;10:1111-4.

75.

Koller KJ , Goeddel DV Molecular biology of the natriuretic peptides and their receptors . Circulation 1992;86:1081-8.

76.

Anand-Srivastava MB Atrial natriuretic peptide-C receptor and membrane signalling in hypertension. J Hypertens 1997 ; 15: 815-26.

77.

Maack T. , Nikonova LN , Friedman O. , Cohen D. Functional properties and dynamics of natriuretic peptide receptors . Proc Soc Exp Biol Med 1996;213:109-16.

78.

Matsukawa N. , Grzesik WJ , Takahashi N. et al.The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system . Proc Natl Acad Sci (USA). 1999; 96: 7403-8.

79.

Mukaddam-Daher S. , Lambert C. , Gutkowska J. Clonidine and ST-91 may activate imidazoline binding sites in the heart to release atrial natriuretic peptide. Hypertension 1997; 30: 83-7. 80. Wilkins MR , Settle SL , Needleman P. Augmentation of the natriuretic activity of exogenous and endogenous atriopeptide in rats by inhibition of cyclic GMP degradation. J Clin Invest 1990;85:1274-9.

80.

Masanori F. , Wada A. , Tsumato T. , Ohnishi M. , Sawaki M. Prevention of cyclic GMP breakdown can enhance the effects of endogenous natriuretic peptides in heart failure. Circulation 1999; 100: 1439(Abstract).

81.

Maack T. , Suzuki M. , Almeida FA , Nussenzweig D. , Scarborough RM et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238: 675-8.

82.

Wei CM , Kim CH , Miller VM , Burnett JCJ . Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide . J Clin Invest 1993;92:2048-52.

83.

Jin H. , Li B. , Cunningham B. et al. Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats. J Clin Invest 1996;98:969-76. 85. Tan Acitl , Russel FG , Thien T. , Benraad, TJ Atrial natriuretic peptide.An overview of clinical pharmacology and pharmacokinetics . Clin Pharmacokinet 1993 ; 24: 28-45.

84.

Hirschberg R. Biologically active peptides in acute renal failure: recent clinical trials. Nephrol Dial Transplant 1997;12:1563-6.

85.

Lewis J. , Salem MM , Chertow GM et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000;36:767-74.

86.

Meyer M. , Uberbacher HJ , Bohm E. , Schope KB , Brett W. , Forssmann WG Ularitide: from renal natriuretic peptide to clinical trials. Curr Opin Nephrol Hypertens 1996;5:364-8.

87.

Lee LS , Hart D. , Packer M. et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure.A double-blind, placebo-controlled, randomized crossover trial. Circulation . 1996;94:3184-9.

88.

Colucci WS , Elkayam U. , Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.

89.

Mills RM , LeJemtel TH , Horton DP et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group.JAm Coll Cardiol 1999;34:155-62.

90.

Grines CL Safety and effectiveness of dofetilide for conversion of atrial fibrillation and nesiritide for acute decompensation of heart failure: a report from the cardiovascular and renal advisory panel of the Food and Drug Administration . Circulation 2000;101:E200-E201.

91.

Roques BP , Noble F. , Dauge V. , Fournie-Zaluski MC , BeaumontA. Neutral endopeptidase 24.11: structure, inhibition and experimental clinical pharmacology. Pharmac Rev 1993; 45:87-146.

92.

Rademaker MT , Charles CJ , Espiner EA et al. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart faiulure. Clin Sci 1996; 91: 283-91.

93.

Erdos EG , Skidgel RA Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989;3:145-51.

94.

Roques BP , Beaumont A.

Neutral endopeptidase-24.11 inhibitors: from analgesics to antihypertensives ?

TIPS 1990; 11: 245-9.

95.

Wilkins MR , Unwin RJ , Kenny AJ Endopeptidase-24.11 and its inhibitors: Potential therapeutic agents for edematous disorders and hypertension. Kidney International 1993;43:273-285. 98. Richards M. , Espiner E. , Frampton C. et al. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension. 1990;16:269-76.

96.

O'Connell JE , Jardine AG , Davies DL , McQueen J. , Connell JM Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man. Clin Sci 1993;85:19-26.

97.

Sagnella GA , Markandu ND , Buckley MG et al. Hormonal and renal responses to neutral endopeptidase inhibition in normal humans on a low and on a high sodium intake . Eur J Clin Invest 1995;25:165-70.

98.

Singer DR , Markandu ND , Buckley MG , Miller MA , Sagnella GA , MacGregor GA Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension. Hypertension 1991;18:798-804.

99.

Bevan EG , Connell JM , Doyle J. et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-13.

100.

Richards AM , Wittert GA , Espiner EA , Yandle TG , Ikram H. , Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers . Circ Res 1992;71:1501-7.

101.

Richards AM , Wittert GA , Crozier IG et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993 ;11:407-16.

102.

Kosoglou T. , Herron JM , Chen R. , Given BD , Sybertz EJ , Affrime MB Antihypertensive effects of the atriopeptidase inhibitor SCH24826 in essential hypertension . Circulation 1990; 82(suppl 3): 554(Abstract).

103.

Elsner D. , Muntze A. , Kromer EP , Riegger GA Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992;70:494-8.

104.

Newby DE , McDonagh T. , Currie PF , Northridge DB , Boon NA , Dargie HJ Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Eur Heart J 1998;19:1808-13.

105.

Northridge DB , Newby DE , Rooney E. , Norrie J. , Dargie HJ Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure . Am Heart J 1999;138:1149-57.

106.

WestheimAS, Bostrom P. , Christensen CC , Parikka H. , Rykke EO , Toivonen L. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. J Am Coll Cardiol 1999;34:1794-801.

107.

Cleland JG , Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. Lancet 1998; 351:1657-8.

108.

Taal MW , Brenner BM Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists . Kidney International 2000 ; 57: 1803-17.

109.

Margulies KB , Perrella MA , McKinley LJ , Burnett JC, Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991;88:1636-42.

110.

Seymour AA , Swerdel JN , Abboa-Offei B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme . J Cardiovasc Pharmacol 1991;17:456-65.

111.

Pham I. , Gonzalez W. , el Amrani AI et al. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension . J Pharmacol Exp Ther. 1993;265:1339-47.

112.

Seymour AA , Asaad MM , Lanoce VM , Langenbacher KM , Fennell SA , Rogers WL Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993;266:872-83.

113.

Stergiou GS , Hannah JA , Bevan EG et al. Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients (Abstract) . J Hypertens 1994;12:1310-1.

114.

Favrat B. , Burnier M. , Nussberger J. et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1995 ;13:797-804.

115.

Gros C. , Noel N. , Souque A. et al. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 1991;88:4210-4.

116.

French JF , Flynn GA , Giroux EL et al. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J Pharmacol Exp Ther 1994;268:180-6.

117.

Gonzalez Vera W. , Fournie-Zaluski MC , Pham I. , Laboulandine I. , Roques BP , Michel JB Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J Pharmacol Exp Ther 1995;272:343-51.

118.

Robl JA , Sun CQ , Stevenson J. et al. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.JMed Chem 1997;40:1570-7.

119.

Chatelain RE , Ghai RD , Trapani AJ et al. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther 1998;284:974-82.

120.

Trippodo NC , Robl JA , Asaad MM , Fox M. , Panchal BC , Schaeffer TR Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998;11: 363-72.

121.

Trippodo NC , Fox M. , Monticello TM , Panchal BC , Asaad MM Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 1999;34:782-90.

122.

Troughton RW , Rademaker MT , Powell JD et al. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Am J Hypertens 2000;13:1110-6.

123.

Lainchbury JG , Burnett Jr JC The cardiac hormone atrial natriuretic peptide mediates hemodynamic actions of dual enzyme inhibition in early left ventricular dysfunction (Abstract). Circulation 1999;100:I-438.

124.

Raut R. , Rouleau JL , Blais CJ et al. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am J Physiol 1999;276:H1769-79.

125.

Rousso P. , Buclin T. , Nussberger J. et al. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100.20, on endocrine and renal functions in healthy volunteers. J Hypertens 1999; 17: 427-37.

126.

Wallis EJ , Ramsay LE , Hettiarachchi J. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.Clin Pharmacol Ther 1998;64:439-49.

127.

Norton GR , Woodiwiss AJ , Hartford C. et al. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens 1999;12:563-71.

128.

Black HR , Chang PI , Reevers RA , Cooper W. , Pouleur H. Monotherapy treatment success rate of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril and amlodipine in mild to moderate hypertension . Am J Hypertens 1999;12:26A (Abstract).

129.

Zusman R. , Atlas S. , Kochlar M. , Adler E. , Levy E. Efficacy and safety of omapatrilat, a vasopeptidase inhibitor. Am J Hypertens 1999;12:125A (Abstract).

130.

Neutel J. , Shepherd A. , Pool J. , Levy E. , Saini R. , Chang PI Antihypertensive efficay of omapatrilat, a vasopeptidase inhibitor, compared with lisonopril. Am J Hypertens 1999 ; 12:124A (Abstract).

131.

Lainchbury JG , Richards AM , Nicholls MG , Espiner EA , Yandle TG Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment . J Clin Endocrin Metab 1999;84:723-9.

132.

McClean DR , Ikram H. , Garlick AH , Richards AM , Nicholls MG , Crozier IG The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000;36:479-86.

133.

Rouleau JL , Pfeffer MA , Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-20.

134.

Hillege HL , Girbes ARJ , De Kam PJ et al. Renal function, neurohormonal activation and survival in patients with chronic heart failure . Circulation 2000;102:203-10.

135.

Messerli FH , Nussberger J. Vasopeptidase inhibition and angio-oedema . Lancet 2000;356:615-20.

Practical implications of current natriuretic peptide research

Abstract

Keywords

Get full access to this article

References